Maalox,p06.19,Macrophages,p08.3,Magic bullet,p07.2,Magnesium,p17.24,Magnesium citrate,p17.24,Magnetic resonance imaging (MRI),p01.3;p02.15,Malabsorption of nutrients,p18.3,Malignant mixed mesodermal tumor uterus,c45.2,Malnutrition,p18.5,Mammography,p34.18;c06.8,Mantle cell lymphoma,c24.15,Marijuana,p17.14,Mastectomy,6,Mechlorethamine,c23.16,Mediastinoscopy,p04.9,Medical codes,p32.3,Meditation,p13.16;p25.9,MEDLARS (Medical Literature Analysis and Retrieval System),p37.16,Medroxyprogesterone,p23.21,Medullary carcinoma,2,Medulloblastoma,2,Megakaryocytic leukemia,c18.29,Megavoltage equipment,p06.8,Megestrol,p17.20;c03.17;c06.27;c29.21;c35.29;c44.20,Melanoma,17,Melphalan,10,Meningioma,c05.1;c05.19;c05.24;c10b.2,Meningitis,p20.5,Menopause,p23.19,Mercaptopurine,chr.p17.13,Meritine,p18.12,Mesna,c24.20;c29.20;c40.17;c46.13,Mesothelioma,13,Metabolic therapies unproven,p13.10,Metaclopramide,chr.p17.14,Metastases,5,Metastatic cancer,10,Methadone,p19.8;p19.13,Methotrexate,16,Methyl cellulose,p17.24,Methyllomustine,c39.24,Methylprednisolone,c28.21,Metoclopramide,c12.26,Microsurgical free flap technique breast reconstruction,rec.6,Midline tumor unknown primary site,c07.13,Milk intolerance,p17.29,Milk of magnesia,p17.24,Mineral oil,p17.25,Minerals,p13.10;p34.7,Mitoguazone,p35.9,Mitomycin-C,16,Mitotane,c01.10;c01.13,Mitoxantrone,11,Mixed cell cancer parathyroid,c32.2,Mixed ductal carcinoma,c35.32,Mixed mesodermal sarcoma uterus,c45.2;c45.4;c45.10,Mohs micrographic surgery,c37.17,Moistir,p17.17,Molar pregnancy,c43.2;c43.13,Mole,4,Monilia,p17.16,Monoamine oxidase inhibitors,c08.13,Monoclonal gammopathy of undetermined significance,c28.6,Monocytes,p04.5,Monocytoid B-cell lymphoma,c24.14,Morphine,p17.23;p19.8;p19.13;p27.6,Mouth diagram,c14b.1,Mouth care,p17.16;p26.10;c14a.5,Mouth sores,p17.18 ,Mouth tumor,c14a.1;c14b.1,MouthKot,p17.17,Mucinous carcinoma,2,Mucoepidermoid anal cancer,c02.1,Mucosa-associated lymphoma,c24.14,Multiple endocrine neoplasia (MEN),6,Multiple hit theory,p01.6;p34.5;p36.4,Multiple myeloma,13,Muscle ache,p08.17,Muscle invasive tumor,c04.4,Muscle weakness,c28.19,Myasthenia gravis,c41.2;c41.4;c41.5;c41.6;c41.9,Mycostatin,p17.18;p18.15;p18.6,Myelodysplastic syndrome,c18.12,Myelogenous leukemia,p36.8,Mylanta,p06.19;p17.18,
male,c06.52,prophylactic,p05.3,radical,c06.19,risk of lymphangiosarcoma,c36.4,and sexuality,p23.9,treatment,c06.19;c06.32,breast,c06.2,thyroid,c01.5;c42.2;c42.22,adult,c05.11;c05.18,child,c10a.2;c10b.2;c10b.6,causes,c25.4,child,c10a.2,defined,c25.1,diagnosis,c25.9,diagram,c25.11,follow-up,c25.27,locations,10,questions to ask,c25.28,recurrence,c25.27,risk factors,c25.5,screening,c25.7,spread,c25.3,staging,c25.11,symptoms,c25.8,treatment,c25.15,types,c25.2,unknown primary site,c07.5,for breast cancer,c06.42,for Hodgkin's disease,c23.16,for melanoma,c25.15,for multiple myeloma,c28.12;c28.20,for ovarian cancer,c29.20,for thyroid cancer,c42.26,in hyperthermia,p10.3,in hyperthermic perfusion,p11.5,potentiated by buthionine sulfoximine,p35.15,side effects,chr.p17.13;c04.4,causes,c26.2,defined,c26.1,diagnosis,c26.7,diagram,c26.2,follow-up,c26.17,questions to ask,c26.18,risk factors,c26.4,screening,c26.5,spread,c26.2,staging,c26.10,symptoms,c26.6,treatment,c26.11,types,c26.1,bone,c27.3;c27.10,brain,c27.3;c27.7,defined,p01.4,liver,c27.3;c27.11,lung,c27.3;c27.9,causes,c27.2,defined,c27.1,diagnosis,c27.4,diagram,c27.7,follow-up,c27.15,questions to ask,c27.16,spread,c27.2,symptoms,c27.3,treatment,c27.7,types,c27.1,for bladder cancer,c04.24,for bone and soft tissue sarcomas,c36.11,for breast cancer,c06.24;c06.41;c06.44,for Hodgkin's disease,c23.15,for Kaposi's sarcoma,c16.16,for lymphoma,c22.7;c24.19,for mesothelioma,c26.11,for osteogenic sarcoma,c10d.8,for stomach cancer,c39.15,for trophoblastic disease,c43.14,for uterine cancer,c44.21,for vaginal cancer,c46.12,for vulvar cancer,c47.15,in chemotherapy,p07.6,related drugs,p35.8;p35.13;p35.16,side effects,chr.p17.13,for anal cancer,c02.11,for bile duct cancer,c03.11,for bladder cancer,c04.18,for breast cancer,c06.53,for cervical cancer,c09.19,for colorectal cancer,c11b.18;c11c.12,for esophageal cancer,c12.13,for gall bladder cancer,c13.11,for liver cancer,c19.11,for lung cancer,c20.18,for pancreatic cancer,c31.11,for stomach cancer,c39.15,for vaginal cancer,c46.10,for vulvar cancer,c47.9,in hyperthermia,p10.3,side effects,chr.p17.13,for bladder cancer,c04.18,for breast cancer,c06.42,for Hodgkin's disease,c23.15,for leukemia,c18.17,for liver cancer,c19.11,for lymphoma,c24.20,for ovarian cancer,c29.20,for uterine cancer,c44.13;c45.11,for vaginal cancer,c46.12,related drugs,p35.10,side effects,chr.p17.13,benign,p01.4,invasive,c43.2;c43.3;c43.9,malignant,c25.1,warning signals,c25.8,breast,c06.2;c06.3,ovary,c29.1,adrenal gland cancer,c01.6,gastrointestinal tract cancer,c08.2,islet cell carcinoma,c15.3,parathyroid cancer,c32.2;c32.3,risk factor,c15.3,thyroid cancer,c42.2;c42.6,causes,c28.3,defined,c28.1,diagnosis,c28.8,diagram,c28.18,follow-up,c28.20,questions to ask,c28.22,recurrent,c28.21,risk factors,c28.5,screening,c28.6,staging,c28.11,symptoms,c28.7,treatment,p12.22;c28.12,types,c28.2,
anus,c02.1;c25.3,brain,c25.3,colorectal,c11a.1,esophagus,c12.2,eye,c25.1;c25.13;c25.21,mouth,c25.3,penis,c32.1,skin,c25.1;c25.11,vagina,c25.1;c46.1;c46.7,vulva,c47.2;c47.17,